Raymond James Financial
KROS icon

Raymond James Financial’s Keros Therapeutics KROS Stock Holding History

Raymond James Financial’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-100
Closed -$1.33K – 5899
2025
Q2 		$1.33K Buy
+100
New +$1.35K ﹤0.01% 6510

Other funds holding KROS

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Raymond James Financial's KROS Position: Q3 2025 in Review

Raymond James Financial sold out of Keros Therapeutics (KROS) in Q3 2025, closing a stake of 100 shares — an estimated $1.33K sold.

Raymond James Financial first reported a position in KROS in Q2 2025 and held it in 1 quarter. The position peaked at $1.33K in Q2 2025. 155 funds tracked by Wall St. Rank hold KROS as of Q3 2025.

  • Raymond James Financial reported no remaining Keros Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 100 Keros Therapeutics shares in Q3 2025, an estimated $1.33K.
  • Raymond James Financial first reported a position in Keros Therapeutics in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Keros Therapeutics position peaked at $1.33K in Q2 2025.
  • 155 funds tracked by Wall St. Rank held Keros Therapeutics as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.